Testosterone and Anterior Cruciate Ligament Injury and Reconstruction Outcomes: A Systematic Review and Meta-analysis.

Authors

Dave Osinachukwu Duru, David Kwan Ryung Lee, Prushoth Vivekanantha, Marc Daniel Bouchard, Osama Alzobi, Loiy Alkhatib, Bashir A Zikria, Ashraf Hantouly, Moin Khan

Published in

Sports health. Pages 19417381261486660. Oct 15, 2026. Epub Oct 15, 2026.

Abstract

Testosterone influences connective tissue biology, neuromuscular performance, and postoperative recovery. However, its clinical impact on anterior cruciate ligament (ACL) injury risk and outcomes after ACL reconstruction (ACLR) remains unclear.
To evaluate the association between testosterone replacement therapy (TRT) or endogenous testosterone levels and ACL tear incidence, ACLR revision, patient-reported outcome measures (PROMs), strength, and complications.
Embase, Ovid MEDLINE, and PubMed were searched from inception to March 14, 2026.
Studies evaluating TRT use or endogenous testosterone levels in relation to ACL tear incidence or outcomes after ACLR were included. Systematic reviews, narrative reviews, scoping reviews, letters, editorials, technical notes, conference abstracts without full-text publication, animal studies, cadaveric studies, case reports, and non-English studies were excluded.
Systematic review and meta-analysis.
Level 3.
Two reviewers independently extracted study characteristics, testosterone exposure, ACL tear incidence, ACLR revision, PROMs, strength outcomes, and complications. Random-effects meta-analyses pooled odds ratios for ACL tear incidence and ACLR revision. Study quality was assessed using the Methodological Index for Non-Randomized Studies and Cochrane Risk of Bias 2.0, and certainty of evidence was assessed using Grading of Recommendations, Assessment, Development and Evaluation.
Seven studies were eligible, comprising 1,178,891 patients, of whom 589,436 were TRT users. TRT use was associated with a significantly increased risk of primary ACL tear within 2 years (odds ratio [OR], 2.83; 95% CI, 1.74-4.62; I² = 95.4%), with consistent findings across sex-specific analyses. In contrast, there was no difference in ACLR revision rates at 2 years (OR 1.04; 95% CI 0.84-1.29; I² = 0%). One randomized trial demonstrated increased early postoperative lean mass with TRT, without differences in strength or PROMs. Increased ACL rupture risk was associated with higher testosterone levels in men, and lower levels in women. Higher testosterone levels did not adversely affect PROMs or complication rates after ACLR.
TRT is associated with increased ACL tear risk at 2 years after initiation but does not appear to affect 2-year ACLR revision rates. Higher endogenous testosterone levels may influence ACL injury susceptibility in a sex-dependent manner, without impairing ACLR recovery.

PMID:
42881560
Bibliographic data and abstract were imported from PubMed on 16 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.